Document:

Exhibit 10.2

 

NEITHER THIS WARRANT NOR ANY OF THE SECURITIES
ISSUABLE UPON EXERCISE OF THIS WARRANT HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933 OR UNDER THE SECURITIES LAWS OF ANY
OTHER JURISDICTION. BY ACQUIRING THIS WARRANT, HOLDER REPRESENTS THAT HOLDER WILL NOT SELL OR OTHERWISE DISPOSE OF THIS WARRANT
OR THE SECURITIES FOR WHICH IT MAY BE EXERCISED WITHOUT REGISTRATION OR COMPLIANCE WITH AN EXEMPTION FROM REGISTRATION UNDER THE
AFORESAID ACTS AND THE RULES AND REGULATIONS THEREUNDER.

 

WARRANT TO PURCHASE COMMON STOCK

 

Number of Shares of Common Stock: [●]

Date of Issuance: [●], 2014 (“Issuance Date”)

 

This
Certifies That, for value received, [●], a [●] (including any permitted and registered assigns, the “Holder”),
is entitled to purchase from Wireless Ronin Technologies, Inc., a Minnesota corporation (the “Company”),
up to [●] shares of Common Stock (the “Warrant Shares”) at the Exercise Price then in effect. This Warrant
to Purchase Common Stock (this “Warrant”) is issued by the Company as of the date hereof pursuant to that certain
Securities Purchase Agreement dated [●], 2014, by and among the Company, Holder and other parties thereto (the “Agreement”).
Capitalized terms used in this Warrant shall have the meanings set forth in the Agreement unless otherwise defined in the body
of this Warrant or in Section 13 below. For purposes of this Warrant, the term “Exercise Price” shall mean $0.50
per share, subject to adjustment as provided herein, and the term “Exercise Period” shall mean the period
commencing on the Issuance Date and ending on 5:00 p.m. New York time on the five-year anniversary thereof.

 

1.EXERCISE OF WARRANT.

 

(a)Mechanics of Exercise. Subject to the terms and
conditions hereof, the rights represented by this Warrant may be exercised in whole or in part at any time or times during the
Exercise Period by delivery of a written notice, in the form attached hereto as Exhibit A (the “Exercise Notice”),
of the Holder’s election to exercise this Warrant. The Holder shall not be required to deliver the original Warrant in order
to effect an exercise hereunder. Execution and delivery of the Exercise Notice with respect to less than all of the Warrant Shares
shall have the same effect as cancellation of the original Warrant and issuance of a new Warrant evidencing the right to purchase
the remaining number of Warrant Shares. On or before the third Trading Day (the “Warrant Share Delivery Date”)
following the date on which the Company shall have received the Exercise Notice, and upon receipt by the Company of (i) payment
to the Company of an amount equal to the applicable Exercise Price multiplied by the number of Warrant Shares as to which this
Warrant is being exercised (the “Aggregate Exercise Price” and together with the Exercise Notice, the “Exercise
Delivery Documents”) in cash or by wire transfer of immediately available funds or (ii) notification from the Holder
that this Warrant is being exercised pursuant to a Cashless Exercise, as defined below, the Company shall (or direct its transfer
agent to) issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered
in the Company’s share register in the name of the Holder or its designee, for the number of shares of Common Stock to which
the Holder is entitled pursuant to such exercise. Upon delivery of the Exercise Delivery Documents, the Holder shall be deemed
for all corporate purposes to have become the holder of record of the Warrant Shares with respect to which this Warrant has been
exercised, irrespective of the date of delivery of the certificates evidencing such Warrant Shares. If this Warrant is submitted
in connection with any exercise pursuant to Section 1(c) and the number of Warrant Shares represented by this Warrant submitted
for exercise is greater than the number of Warrant Shares being acquired upon an exercise, then the Company shall as soon as practicable
and in no event later than three business days after any exercise and at its own expense, issue a new Warrant (in accordance with
Section 6) representing the right to purchase the number of Warrant Shares purchasable immediately prior to such exercise under
this Warrant, less the number of Warrant Shares with respect to which this Warrant is exercised.

 

    	 

    	 

    

 

(b)No Fractional Shares. No fractional shares shall
be issued upon the exercise of this Warrant as a consequence of any adjustment pursuant hereto. All Warrant Shares (including fractions)
issuable upon exercise of this Warrant may be aggregated for purposes of determining whether the exercise would result in the issuance
of any fractional share. If, after aggregation, the exercise would result in the issuance of a fractional share, the Company shall,
in lieu of issuance of any fractional share, pay the Holder otherwise entitled to such fraction a sum in cash equal to the product
resulting from multiplying the then-current fair market value of a Warrant Share by such fraction.

 

(c)Cashless Exercise. The Holder may, in its sole
discretion, exercise this Warrant in whole or in part and, in lieu of making the cash payment otherwise contemplated to be made
to the Company upon such exercise in payment of the Aggregate Exercise Price, elect instead to receive upon such exercise the “Net
Number” of shares of Common Stock determined according to the following formula (a “Cashless Exercise”):

 

Net Number = (A x B) - (A x C)

                                              B

 

For purposes of the foregoing formula:

 

A =the total number of shares with
respect to which this Warrant is then being exercised.

 

B = the Weighted Average Price
of the shares of Common Stock for the five consecutive Trading Days ending on the date immediately preceding the date of the Exercise
Notice.

 

C = the Exercise Price then in
effect for the applicable Warrant Shares at the time of such exercise.

 

    	2

    	 

    

 

(d)Compensation for Buy-In on Failure to
Timely Deliver Warrant Shares. In addition to any other rights available to the Holder, if the Company fails to deliver (or
cause its transfer agent to deliver) to the Holder the Warrant Shares pursuant to an exercise on or before the Warrant Share Delivery
Date, and if after such date the Holder is required by its broker to purchase (in an open-market transaction or otherwise), or
the Holder’s brokerage firm otherwise purchases, shares of Common Stock to deliver in satisfaction of a sale by the Holder
of the Warrant Shares which the Holder anticipated receiving upon such exercise (a “Buy-In”), then the Company
shall (A) pay in cash to the Holder the amount, if any, by which (x) the Holder’s total purchase price (including brokerage
commissions, if any) for the shares of Common Stock so purchased exceeds (y) the amount obtained by multiplying (1) the number
of Warrant Shares that the Company was required to deliver to the Holder in connection with the exercise at issue, times (2) the
price at which the sell order giving rise to such purchase obligation was executed, and (B) at the option of the Holder, either
reinstate the portion of the Warrant and equivalent number of Warrant Shares for which such exercise was not honored (in which
case such exercise shall be deemed rescinded) or deliver to the Holder the number of shares of Common Stock that would have been
issued had the Company timely complied with its exercise and delivery obligations hereunder. For example, if the Holder purchases
Common Stock having a total purchase price of $11,000 to cover a Buy-In with respect to an attempted exercise of shares of Common
Stock with an aggregate sale price giving rise to such purchase obligation of $10,000, under clause (A) of the immediately preceding
sentence the Company shall be required to pay the Holder $1,000. The Holder shall provide the Company written notice indicating
the amount payable to the Holder in respect of the Buy-In and, upon request of the Company, evidence of the amount of such loss.
Nothing herein shall limit a Holder’s right to pursue any other remedies available to it hereunder, at law or in equity,
including without limitation a decree of specific performance or other injunctive relief with respect to the Company’s failure
to timely deliver shares of Common Stock upon exercise of the Warrant as required pursuant to the terms hereof.

 

(e)Holder’s Exercise Limitations.
The Company shall not effect any exercise of this Warrant, and a Holder shall not have the right to exercise any portion of this
Warrant, to the extent that after giving effect to issuance of Warrant Shares upon exercise as set forth on the applicable Notice
of Exercise, the Holder (together with the Holder’s “affiliates,” as such term is defined in Rule 405 under the
Securities Act of 1933, and any other persons acting as a group together with the Holder or any of the Holder’s affiliates),
would beneficially own in excess of the Beneficial Ownership Limitation, as defined below. For purposes of the foregoing sentence,
the number of shares of Common Stock beneficially owned by the Holder and its affiliates shall include the number of shares of
Common Stock issuable upon exercise of this Warrant with respect to which such determination is being made, but shall exclude the
number of shares of Common Stock which would be issuable upon (i) exercise of the remaining, non-exercised portion of this Warrant
beneficially owned by the Holder or any of its affiliates and (ii) exercise or conversion of the unexercised or non-converted portion
of any other securities of the Company (including without limitation any other Common Stock Equivalents) subject to a limitation
on conversion or exercise analogous to the limitation contained herein beneficially owned by the Holder or any of its affiliates.
Except as set forth in the preceding sentence, for purposes of this paragraph (e), beneficial ownership shall be calculated in
accordance with Section 13(d) of the Securities Exchange Act of 1934 and the rules and regulations thereunder (the “Exchange
Act”), it being acknowledged by the Holder that the Company is not representing to the Holder that such calculation is
in compliance with Section 13(d) of the Exchange Act and the Holder is solely responsible for any schedules required to be filed
in accordance therewith. To the extent that the limitation contained in this paragraph applies, the determination of whether this
Warrant is exercisable (in relation to other securities owned by the Holder together with any affiliates) and of which portion
of this Warrant is exercisable shall be in the sole discretion of the Holder, and the submission of a Notice of Exercise shall
be deemed to be the Holder’s determination of whether this Warrant is exercisable (in relation to other securities owned
by the Holder together with any Affiliates) and of which portion of this Warrant is exercisable, in each case subject to the Beneficial
Ownership Limitation, and the Company shall have no obligation to verify or confirm the accuracy of such determination.

 

    	3

    	 

    

 

For purposes of this paragraph, in determining
the number of outstanding shares of Common Stock, a Holder may rely on the number of outstanding shares of Common Stock as reflected
in (A) the Company’s most recent periodic or annual report filed with the SEC, as the case may be, (B) a more recent public
announcement by the Company or (C) a more recent written notice by the Company or its transfer agent setting forth the number of
shares of Common Stock outstanding. Upon the request of a Holder, the Company shall within two Trading Days confirm to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder or its affiliates
since the date as of which such number of outstanding shares of Common Stock was reported. The “Beneficial Ownership Limitation”
shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares
of Common Stock issuable upon exercise of this Warrant. Upon no fewer than 61 days’ prior notice to the Company, a Holder
may increase or decrease the Beneficial Ownership Limitation provisions of this paragraph, provided that the Beneficial Ownership
Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to
the issuance of shares of Common Stock upon exercise of this Warrant held by the Holder and the provisions of this paragraph shall
continue to apply. Any such increase or decrease will not be effective until the 61st day after such notice is delivered to the
Company and shall only apply to such Holder and no other Holder. The limitations contained in this paragraph shall apply to a successor
Holder of this Warrant.

 

2.ADJUSTMENTS. The Exercise Price and the number
of Warrant Shares shall be adjusted from time to time as follows:

 

(a)Subdivision or Combination of Common Stock. If
the Company at any time on or after the Issuance Date subdivides (by any stock split, stock dividend, recapitalization or otherwise)
one or more classes of its outstanding shares of Common Stock into a greater number of shares, the Exercise Price in effect immediately
prior to such subdivision will be proportionately reduced and the number of Warrant Shares will be proportionately increased. If
the Company at any time on or after the Issuance Date combines (by combination, reverse stock split or otherwise) one or more classes
of its outstanding shares of Common Stock into a smaller number of shares, the Exercise Price in effect immediately prior to such
combination will be proportionately increased and the number of Warrant Shares will be proportionately decreased. Any adjustment
under this Section 2(a) shall become effective at the close of business on the date the subdivision or combination becomes effective.

 

(b)Distribution of Assets. If the Company shall declare
or make any dividend or other distribution of its assets (or rights to acquire its assets) to holders of shares of Common Stock,
by way of return of capital or otherwise (including without limitation any distribution of cash, stock or other securities, property
or options by way of a dividend, spin off, reclassification, corporate rearrangement or other similar transaction) (a “Distribution”),
at any time after the issuance of this Warrant, then, in each such case:

 

(i)any Exercise Price in effect
immediately prior to the close of business on the record date fixed for the determination of holders of shares of Common Stock
entitled to receive the Distribution shall be reduced, effective as of the close of business on such record date, to a price determined
by multiplying such Exercise Price by a fraction (i) the numerator of which shall be the Closing Sale Price of the shares of Common
Stock on the Trading Day immediately preceding such record date minus the value of the Distribution (as determined in good faith
by the Company’s Board of Directors) applicable to one share of Common Stock, and (ii) the denominator of which shall be
the Closing Sale Price of the shares of Common Stock on the Trading Day immediately preceding such record date; and

 

    	4

    	 

    

 

(ii)the number of Warrant Shares
shall be increased to a number of shares equal to the number of shares of Common Stock obtainable immediately prior to the close
of business on the record date fixed for the determination of holders of shares of Common Stock entitled to receive the Distribution
multiplied by the reciprocal of the fraction set forth in the immediately preceding clause (i); provided, however, that in the
event that the Distribution is of shares of common stock of a company (other than the Company) whose common stock is traded on
a national securities exchange or a national automated quotation system (“Other Shares of Common Stock”), then
the Holder may elect to receive a warrant to purchase Other Shares of Common Stock in lieu of an increase in the number of Warrant
Shares, the terms of which shall be identical to those of this Warrant, except that such warrant shall be exercisable into the
number of shares of Other Shares of Common Stock that would have been payable to the Holder pursuant to the Distribution had the
Holder exercised this Warrant immediately prior to such record date and with an aggregate exercise price equal to the product of
the amount by which the exercise price of this Warrant was decreased with respect to the Distribution pursuant to the terms of
the immediately preceding clause (i) and the number of Warrant Shares calculated in accordance with the first part of this clause
(ii).

 

(c)Potential Reduction in Exercise Price. If
the Company fails to file the Resale Registration Statement with the SEC within 90 days after obtaining the Shareholder Approval,
or the Resale Registration Statement is not declared effective by the SEC within six months after obtaining the Shareholder Approval
(each such date, a “Deadline”), the Exercise Price shall be reduced by $0.025 per Warrant Share for each full
calendar month past the Deadline in which the Resale Registration Statement remains unfiled or not declared effective, as applicable;
provided, however, that, notwithstanding anything herein, the Exercise Price shall not be reduced pursuant to this paragraph
(c) during any such time as Warrant Shares may be sold pursuant to Rule 144.

 

(d)Weighted-Average
Adjustment to Exercise Price. If the Company, at any time while this Warrant is outstanding, shall issue any Common Stock or
Common Stock Equivalents entitling any person to acquire shares of Common Stock, at an effective price per share less than the
then-current Exercise Price, as adjusted hereunder (any such issuance, other than an issuance of Common Stock or Common Stock Equivalents
in respect of an Exempt Issuance, being referred to as a “Dilutive Issuance”), then the Exercise Price
shall be adjusted in accordance with the following formula:

 

AEP = EP * [OS + ((DIS *
DIP)/EP)]

                                                 (OS + DIS)

 

    	5

    	 

    

 

For purposes of the foregoing formula:

 

AEP =Adjusted Exercise Price

 

EP =Exercise Price (as in
effect immediately prior to adjustment)

 

OS=Total number of shares
of Common Stock and Common Stock Equivalents outstanding immediately prior to the Dilutive (excluding, however, Common Stock and
Common Stock Equivalents outstanding on account of Exempt Issuances)

 

DIS=Total number of shares
of Common Stock and Common Stock Equivalents issued in the Dilutive Issuance

 

DIP =The per-share price at
which Common Stock or Common Stock Equivalents were issued in the Dilutive Issuance

 

Any such adjustment shall
be made whenever such Common Stock or Common Stock Equivalents are issued; provided, however, that (i) if an adjustment is made
on account of a Dilutive Issuance of Common Stock Equivalents, then the subsequent issuance of actual Common Stock upon conversion
or exercise of such Common Stock Equivalents will not result in a second adjustment, and (ii) notwithstanding anything in this
Warrant to the contrary, no adjustments shall be made under this Section 3(d) in respect of an Exempt Issuance. The Company shall
notify the Holder in writing, no later than the third Trading Day following any Dilutive Issuance (other than an Exempt Issuance),
indicating therein the applicable per-share price at which Common Stock or Common Stock Equivalents were issued (such notice the
“Dilutive Issuance Notice”).

 

3.FUNDAMENTAL TRANSACTIONS.

 

(a)Survival of Warrant. If, at any
time while this Warrant is outstanding, (i) the Company effects any merger of the Company with or into another entity and the Company
is not the surviving entity (such surviving entity, the “Successor Entity”), (ii) the Company effects any sale
of all or substantially all of its assets in one or a series of related transactions, (iii) any tender offer or exchange offer
(whether by the Company or by another individual or entity, and approved by the Company) is completed pursuant to which holders
of Common Stock are permitted to tender or exchange their shares of Common Stock for other securities, cash or property and the
holders of at least 50% of the Common Stock accept such offer, or (iv) the Company effects any reclassification of the Common Stock
or any compulsory share exchange pursuant to which the Common Stock is effectively converted into or exchanged for other securities,
cash or property (other than as a result of a subdivision or combination of shares of Common Stock covered by Section 2(a) above)
(in any such case, a “Fundamental Transaction”), then, upon any subsequent exercise of this Warrant, the Holder
shall have the right to receive the number of shares of Common Stock of the Successor Entity or of the Company and any additional
consideration (the “Alternate Consideration”) receivable upon or as a result of such reorganization, reclassification,
merger, consolidation or disposition of assets by a holder of the number of shares of Common Stock for which this Warrant is exercisable
immediately prior to such event (disregarding any limitation on exercise contained herein solely for the purpose of such determination).
For purposes of any such exercise, the determination of the Exercise Price shall be appropriately adjusted to apply to such Alternate
Consideration based on the amount of Alternate Consideration issuable in respect of one share of Common Stock in such Fundamental
Transaction, and the Company shall apportion the Exercise Price among the Alternate Consideration in a reasonable manner reflecting
the relative value of any different components of the Alternate Consideration. If holders of Common Stock are given any choice
as to the securities, cash or property to be received in a Fundamental Transaction, then the Holder shall be given the same choice
as to the Alternate Consideration it receives upon any exercise of this Warrant following such Fundamental Transaction. To the
extent necessary to effectuate the foregoing provisions, any Successor Entity in such Fundamental Transaction shall issue to the
Holder a new warrant consistent with the foregoing provisions and evidencing the Holder’s right to exercise such warrant
into Alternate Consideration.

 

    	6

    	 

    

 

(b)Payoff Option. Notwithstanding anything
to the contrary, in the event of a Fundamental Transaction, the Company or any Successor Entity shall, at the Holder’s option,
exercisable at any time concurrently with, or within 30 days after, the consummation of the Fundamental Transaction, purchase this
Warrant from the Holder by paying to the Holder an amount of cash equal to the Black-Scholes Value of the remaining unexercised
portion of this Warrant as of the date of the consummation of such Fundamental Transaction. “Black-Scholes Value”
means the value of this Warrant based on the Black-Scholes Option Pricing Model obtained from the “OV” function on
Bloomberg, determined as of the day of consummation of the applicable Fundamental Transaction for pricing purposes and reflecting
(A) a risk-free interest rate corresponding to the U.S. Treasury rate for a period equal to the time between the date of the public
announcement of the applicable Fundamental Transaction and the Termination Date, and (B) an expected volatility equal to the greater
of 100% and the 100-day volatility obtained from the HVT function on Bloomberg as of the Trading Day immediately following the
public announcement of the applicable Fundamental Transaction, and (C) the underlying price per share used in such calculation
shall be the sum of the price per share being offered in cash, if any, plus the value of any non-cash consideration, if any, being
offered in such Fundamental Transaction and (D) a remaining option time equal to the time between the date of the public announcement
of the applicable Fundamental Transaction and the expiration date of this Warrant.

 

4.NON-CIRCUMVENTION. The Company covenants and agrees
that it will not, by amendment of its articles of incorporation, bylaws or through any reorganization, transfer of assets, consolidation,
merger, scheme of arrangement, dissolution, issue or sale of securities, or any other voluntary action, avoid or seek to avoid
the observance or performance of any of the terms of this Warrant, and will at all times in good faith carry out all the provisions
of this Warrant and take all action as may be required to protect the rights of the Holder. Without limiting the generality of
the foregoing, the Company (i) shall not increase the par value of any shares of Common Stock receivable upon the exercise of this
Warrant above the Exercise Price then in effect, (ii) shall take all such actions as may be necessary or appropriate in order that
the Company may validly and legally issue fully paid and non-assessable shares of Common Stock upon the exercise of this Warrant,
and (iii) shall, after obtaining the Shareholder Approval, for so long as this Warrant is outstanding, have authorized and reserved,
free from preemptive rights, a sufficient number of shares of Common Stock to provide for the exercise of the rights represented
by this Warrant (without regard to any limitations on exercise).

 

5.WARRANT HOLDER NOT DEEMED A SHAREHOLDER. Except
as otherwise specifically provided herein, this Warrant, in and of itself, shall not entitle the Holder to any voting rights or
other rights as a shareholder of the Company. In addition, nothing contained in this Warrant shall be construed as imposing any
liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a shareholder of the Company,
whether such liabilities are asserted by the Company or by creditors of the Company.

 

    	7

    	 

    

 

6.REISSUANCE.

 

(a)Lost, Stolen or Mutilated Warrant. If this Warrant
is lost, stolen, mutilated or destroyed, the Company will, on such terms as to indemnity or otherwise as it may reasonably impose
(which shall, in the case of a mutilated Warrant, include the surrender thereof), issue a new Warrant of like denomination and
tenor as this Warrant so lost, stolen, mutilated or destroyed.

 

(b)Issuance of New Warrants. Whenever the Company
is required to issue a new Warrant pursuant to the terms of this Warrant, such new Warrant shall be of like tenor with this Warrant,
and shall have an issuance date, as indicated on the face of such new Warrant which is the same as the Issuance Date.

 

7.TRANSFER.

 

(a)Notice of Transfer. The Holder, by acceptance
hereof, agrees to give written notice to the Company before transferring this Warrant or transferring any Warrant Shares of such
Holder’s intention to do so, describing briefly the manner of any proposed transfer. Promptly upon receiving such written
notice, the Company shall present copies thereof to the Company’s counsel. If the proposed transfer may be effected without
registration or qualification (under any federal or state securities laws), the Company, as promptly as practicable, shall notify
the Holder thereof, whereupon the Holder shall be entitled to transfer this Warrant or to dispose of Warrant Shares received upon
the previous exercise of this Warrant, all in accordance with the terms of the notice delivered by the Holder to the Company; provided,
however, that an appropriate legend may be endorsed on this Warrant or the certificates for such Warrant Shares respecting restrictions
upon transfer thereof necessary or advisable in the opinion of counsel and satisfactory to the Company to prevent further transfers
which would be in violation of Section 5 of the Securities Act of 1933 and applicable state securities laws; and provided further
that the prospective transferee or purchaser shall execute the Assignment of Warrant attached hereto as Exhibit B and such
other documents and make such representations, warranties, and agreements as may be required solely to comply with the exemptions
relied upon by the Company for the transfer or disposition of the Warrant or Warrant Shares.

 

(b)If the proposed transfer or disposition of this Warrant
or such Warrant Shares described in the written notice given pursuant to this Section 7 may not be effected without registration
or qualification of this Warrant or such Warrant Shares, the Holder will limit its activities in respect to such transfer or disposition
as are permitted by law.

 

(c)Any transferee of all or a portion of this
Warrant shall succeed to the rights and benefits of the initial Holder of this Warrant under Sections 4.2 (subject, however, to
the limitations set forth in Section 4.3), 4.4, 4.6 and 4.7 of the Agreement (registration rights, expenses, indemnity and reservation
of securities).

 

    	8

    	 

    

 

8.NOTICES. Whenever notice is required
to be given under this Warrant, unless otherwise provided herein, such notice shall be given in accordance with the notice provisions
contained in the Agreement. The Company shall provide the Holder with prompt written notice (i) immediately upon any adjustment
of the Exercise Price, setting forth in reasonable detail, the calculation of such adjustment and (ii) at least 20 days prior to
the date on which the Company closes its books or takes a record (A) with respect to any dividend or distribution upon the shares
of Common Stock, (B) with respect to any grants, issuances or sales of any stock or other securities directly or indirectly convertible
into or exercisable or exchangeable for shares of Common Stock or other property, pro rata to the holders of shares of Common Stock
or (C) for determining rights to vote with respect to any Fundamental Transaction, dissolution or liquidation, provided in each
case that such information shall be made known to the public prior to or in conjunction with such notice being provided to the
Holder.

 

9.AMENDMENT AND WAIVER. The terms of this Warrant
may be amended or waived (either generally or in a particular instance and either retroactively or prospectively) only with the
written consent of the Company and the Holder. In addition, the restrictions set forth in Section 1(e) can be waived, as to a particular
original purchaser of Series A Preferred Stock and its affiliates, pursuant to a writing signed and delivered by the Company and
such original Purchaser prior to the execution and delivery of this Warrant.

 

10.GOVERNING LAW. This Warrant and all rights, obligations
and liabilities hereunder shall be governed by, and construed in accordance with, the internal laws of the State of New York, without
giving effect to the conflicts-of-law principles thereof.

 

11.DISPUTE RESOLUTION. A dispute as to the determination
of the Exercise Price, the Closing Sale Price, or the arithmetic calculation of the Warrant Shares, the Company or the Holder (as
the case may be) shall submit the disputed determinations or arithmetic calculations via facsimile (a) within two business days
after receipt of the applicable notice giving rise to such dispute to the Company or the Holder, as the case may be, or (b) if
no notice gave rise to such dispute, at any time after the Holder learned of the circumstances giving rise to such dispute. If
the Holder and the Company are unable to agree upon such determination or calculation of the Exercise Price, Closing Sale Price
or the Warrant Shares within three business days of such disputed determination or arithmetic calculation being submitted to the
Company or the Holder, as the case may be, then the Company shall, within two business days thereafter submit via facsimile (x)
the disputed determination of the Exercise Price or Closing Sale Price to an independent, reputable investment bank selected by
the Company and approved by the Holder or (y) the disputed arithmetic calculation of the Warrant Shares to the Company’s
independent, outside accountant. The Company shall cause at its expense the investment bank or the accountant, as the case may
be, to perform the determinations or calculations and notify the Company and the Holder of the results no later than ten business
days from the time it receives the disputed determinations or calculations. Such investment bank’s or accountant’s
determination or calculation, as the case may be, shall be binding upon all parties absent manifest error.

 

12.ACCEPTANCE. Receipt of this Warrant by the Holder
shall constitute acceptance of and agreement to all of the terms and conditions contained herein.

 

13.CERTAIN DEFINITIONS. For purposes of this Warrant,
the following terms shall have the following meanings:

 

(a)“Bloomberg” means Bloomberg Financial
Markets.

 

    	9

    	 

    

  

(b)“Closing Sale Price” means, for any
security as of any date, (i) the last closing trade price for such security on the Principal Market, as reported by Bloomberg,
or, if the Principal Market begins to operate on an extended hours basis and does not designate the closing trade price, then the
last trade price of such security prior to 4:00 p.m., New York time, as reported by Bloomberg, or (ii) if the foregoing does
not apply, the last trade price of such security in the over-the-counter market for such security as reported by Bloomberg, or
(iii) if no last trade price is reported for such security by Bloomberg, the average of the bid and ask prices of any market makers
for such security as reported by the OTC Markets. If the Closing Sale Price cannot be calculated for a security on a particular
date on any of the foregoing bases, the Closing Sale Price of such security on such date shall be the fair market value as mutually
determined by the Company and the Holder. All such determinations to be appropriately adjusted for any stock dividend, stock split,
stock combination or other similar transaction during the applicable calculation period.

 

(c)“Common Stock” means (i) the Company’s
common stock, par value $0.01 per share, and (ii) any share capital into which such common stock shall have been changed or any
share capital resulting from a reclassification of such common stock.

 

(d)“Common Stock Equivalents” means any
securities of the Company that would entitle the holder thereof to acquire at any time Common Stock, including without limitation
any debt, preferred stock, rights, options, warrants or other instrument that is at any time convertible into or exercisable or
exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock.

 

(e)“Exempt Issuance” means the issuance
of (i) shares of Common Stock or options to employees, officers, directors or consultants of the Company pursuant to any stock
or option plan duly adopted by a majority of the non-employee members of the Board of Directors of the Company or a majority of
the members of a committee of non-employee directors established for such purpose, (ii) any securities upon the exercise or conversion
of any securities issued pursuant to the Purchase Agreement, (iii) any Common Stock upon the exercise or conversion of securities
that are issued and outstanding as of the date of the Purchase Agreement, (iv) securities issued pursuant to acquisitions or strategic
transactions approved by a majority of the disinterested directors of the Company, including without limitation all securities
issued in connection with the merger transaction pursuant to which the Company will obtain ownership of the business of Creative
Realities, LLC, (v) shares of Common Stock issued in connection with regularly scheduled dividend payments on the Series A
Preferred Stock, and (vi) shares of Common Stock issued pursuant to any loan or leasing arrangement, real property leasing arrangement,
or debt financing from a bank approved by the Board of Directors of the Company.

 

(d)“Principal Market” means the primary
national securities exchange on which the Common Stock is then traded.

 

(e)“SEC” means the U.S. Securities and
Exchange Commission.

 

(f)“Trading Day” means
(i) any day on which the Common Stock is listed or quoted and traded on its Principal Market, (ii) if the Common Stock is not then
listed or quoted and traded on any national securities exchange, then a day on which trading occurs on any over-the-counter markets,
or (iii) if trading does not occur on the over-the-counter markets, any business day.

 

    	10

    	 

    

  

(g)“Weighted Average Price” means, for
any security as of any date, (i) the dollar-volume weighted-average price for such security on the Principal Market during the
period beginning at 9:30 a.m., New York City time, and ending at 4:00 p.m., New York City time, as reported by Bloomberg or (ii)
if the foregoing does not apply, the dollar-volume weighted-average price of such security in the principal over-the-counter market
for such security during the period beginning at 9:30 a.m., New York City time, and ending at 4:00 p.m., New York City time, as
reported by Bloomberg, or (iii) if no dollar-volume weighted-average price is reported for such security by Bloomberg for such
hours, the average of the highest closing bid price and the lowest closing ask price of any of the market makers for such security
as reported in OTC Markets. If the Weighted Average Price cannot be calculated for such security on such date on any of the foregoing
bases, the Weighted Average Price of such security on such date shall be the fair market value as mutually determined by the Company
and the Holder. If the Company and the Holder are unable to agree upon the fair market value of such security, then such dispute
shall be resolved pursuant to Section 11 with the term “Weighted Average Price” being substituted for the term “Exercise
Price.” All such determinations shall be appropriately adjusted for any share dividend, share split or other similar transaction
during such period.

  

* * * * * * *

 

    	11

    	 

    

  

In Witness
Whereof, the Company has caused this Warrant to Purchase Common Stock to be duly executed as of the Issuance Date set forth
above.

 

	 	WIRELESS RONIN TECHNOLOGIES, INC.
	 	 
	 	 
	 	John Walpuck
	 	Chief Financial Officer

  

    	 

    	 

    

 

EXHIBIT A

 

EXERCISE NOTICE

 

(To be executed by the registered holder to
exercise this Warrant to Purchase Common Stock)

 

The Undersigned
holder hereby exercises the right to purchase _________________ of the shares of Common Stock (“Warrant Shares”) of
Wireless Ronin Technologies, Inc., a Minnesota corporation (the “Company”), evidenced by the attached copy of the Warrant
to Purchase Common Stock (the “Warrant”). Capitalized terms used herein and not otherwise defined shall have the
respective meanings set forth in the Warrant.

 

		1.	Form of Exercise Price. The Holder intends that payment of the Exercise Price shall be made as (check one):

 

		☐	a cash exercise with respect to _________________ Warrant Shares; and/or

 

		☐	a “Cashless Exercise” with respect to _______________ Warrant Shares.

 

		2.	Payment of Exercise Price. In the event that the holder has elected a cash exercise with respect to some or all of the
Warrant Shares to be issued pursuant hereto, the holder shall pay the Aggregate Exercise Price in the sum of $___________________
to the Company in accordance with the terms of the Warrant.

 

		3.	Delivery of Warrant Shares. The Company shall deliver to the holder __________________ Warrant Shares in accordance
with the terms of the Warrant.

 

	Date:  	 	 	 	 
	 	 	 	 	 
	 	 	 	(Print Name of Registered Holder)
	 	 	 	 	 
	 	 	 	By:  	 
	 	 	 	Name:  	 
	 	 	 	Title:  	 

  

    	 

    	 

    

  

EXHIBIT B

 

ASSIGNMENT OF WARRANT

 

(To be signed only upon authorized transfer
of the Warrant)

 

 

For Value
Received, the undersigned hereby sells, assigns, and transfers unto ____________________ the right to purchase _______________
shares of common stock of Wireless Ronin Technologies, Inc., to which the within Warrant to Purchase Common Stock relates and appoints
____________________, as attorney-in-fact, to transfer said right on the books of Wireless Ronin Technologies, Inc. with full power
of substitution and re-substitution in the premises. By accepting such transfer, the transferee has agreed to be bound in all respects
by the terms and conditions of the within Warrant.

  

	Dated:	 	 	 
	 	 	 	 
	 	 	 	 
	 	 	 	(Signature)*
	 	 	 	 
	 	 	 	 
	 	 	 	(Name)
	 	 	 	 
	 	 	 	 
	 	 	 	(Address)
	 	 	 	 
	 	 	 	 
	 	 	 	(Social Security
    or Tax Identification No.)

  

* The signature on this Assignment of Warrant must correspond to
the name as written upon the face of the Warrant to Purchase Common Stock in every particular without alteration or enlargement
or any change whatsoever. When signing on behalf of a corporation, partnership, trust or other entity, please indicate your position(s)
and title(s) with such entity.Exhibit
10.3 

 

EXECUTIVE
EMPLOYMENT AGREEMENT

 

THIS
EXECUTIVE EMPLOYMENT AGREEMENT (“Agreement”) is made and entered into effective as of August 20, 2014 (the
“Effective Date”), by and between Wireless Ronin Technologies, Inc., a Minnesota corporation (the “Company”),
and Paul Price, a resident of the State of New York (“Executive”).

 

BACKGROUND

 

The
Company desires to employ the Executive as its Chief Executive Officer and Executive desires to accept such employment. Among
other things, this Agreement provides for base compensation for Executive, a term of employment and severance payments in certain
circumstances.

 

In
consideration of the foregoing, the Company and Executive hereby agree as follows:

 

Article
1

EMPLOYMENT

 

1.01The
Company hereby agrees to employ Executive subject to and pursuant to the terms of this Agreement, and Executive agrees to such
employment as the Company’s Chief Executive Officer, and shall hold such titles under the terms of this Agreement. The parties
anticipate that Executive will initially perform his services primarily at the Company’s offices in New York, New York,
but that Executive shall also travel on business as advisable and at times work remotely, with the expectation that Executive
will use his good-faith business judgment to determine the appropriate locations to effectively perform his services.

 

1.02Executive
shall generally have the authority, responsibilities, and such duties as are customarily performed by the chief executive officer
of a public company of similar size and industry. Executive shall also render such additional services and duties within the scope
of Executive’s experience and expertise as may be reasonably requested of him from time to time by the Board of Directors
of the Company (the “Board”). Furthermore, the Board may from time to time in its discretion redefine the duties
and responsibilities of Executive as it determines the needs of the Company require, so long as such duties are generally consistent
with the Executive’s title.

 

1.03Executive
shall report to the Board or any committee thereof as the Board shall direct, and shall generally be subject to the direction,
orders, and advice of the Board.

 

Article
2

BEST
EFFORTS OF EXECUTIVE

 

2.01Executive
shall use his best efforts, judgment, and abilities in the performance of his duties, services and responsibilities for the Company.

 

2.02During
the term of his employment, Executive shall devote substantially all of his business time and attention (other than during periods
of vacation, illness or disability) to the business of the Company and its subsidiaries and affiliates and shall not engage in
any substantial activity inconsistent with the foregoing, whether or not such activity shall be engaged in for pecuniary gain,
unless approved by the Board. Notwithstanding the foregoing, Executive may manage his personal investments, engage in educational,
charitable or other community activities, and business advisory capacities as long as such activities do not pose an actual or
apparent conflict of interest and do not interfere with Executive’s performance of his duties under this Agreement. Executive
represents that any outside professional activities with which he is currently involved or reasonably expects to become involved
do not conflict with the business and affairs of the Company or interfere with Executive’s performance of his duties hereunder.

 

    	1

 

    	 

    

 

Article
3

TERM
AND NATURE OF EMPLOYMENT

 

3.01Executive’s
employment on the basis described in this Agreement shall commence on the Effective Date and will terminate on the one-year anniversary
of the Effective Date unless terminated earlier as described in this Agreement. Neither the Company nor Executive shall be obligated
to extend the term of this Agreement. However, the initial one-year term shall automatically be extended for successive one-year
periods unless the Company or Executive elects not to do so by giving written notice to the other not less than 90 days prior
to the end of the then-current term.

 

3.02The
terms and conditions of this Agreement may be amended from time to time with the consent of the Company and Executive. All such
amendments shall be effective when memorialized by a written agreement between the Company and Executive, following approval by
the Board or the Board’s Compensation Committee (the “Committee”). Executive’s employment with
the Company shall at all times be on an “at will” basis, meaning that either Executive or the Company may terminate
the employment relationship at any time for any reason or no reason; provided, however, that Executive may be entitled to certain
compensation upon termination to the extent provided in Section 6.03.

 

Article
4

COMPENSATION
AND BENEFITS

 

4.01During
the initial term of employment, Executive shall be paid a base salary at an annualized rate of $400,000 per year (“Base
Salary”), payable in accordance with the Company’s established payroll periods, and reduced by all deductions
and withholdings required by law and as otherwise specified by Executive. The Board or Committee agrees to review Executive’s
performance and compensation in 2015 and annually thereafter. Executive’s Base Salary may be increased (but not decreased)
in the sole discretion of the Board or Committee; provided, however, that Executive’s Base Salary may be reduced in connection
with compensation reductions applied to all other senior executives of the Company.

 

4.02During
the term of employment, and in addition to payments of Base Salary set forth above, Executive shall be eligible to participate
in the performance-based cash bonus (e.g., the 2014 Senior Management Bonus Plan) or equity award plan for senior executives of
the Company, based upon achievement of individual and/or Company goals established by the Board or Committee.

 

    	2

    	 

    

 

4.03During
the term of employment, Executive shall be entitled to participate in employee benefit plans, policies, programs, perquisites
and arrangements, as the same may be provided and amended from time to time, that are provided generally to similarly situated
executive employees of the Company, to the extent Executive meets the eligibility and other requirements for any such plan, policy,
program, perquisite or arrangement.

 

4.04The
Company shall reimburse Executive for all reasonable business expenses incurred by Executive in carrying out Executive’s
duties, services, and responsibilities under this Agreement, subject to Executive’s compliance with generally applicable
policies, practices and procedures of the Company (as the same may be changed from time to time) with respect to reimbursement
for, and submission of expense reports, receipts or similar documentation of, such expenses.

 

Article
5

VACATION
AND LEAVE OF ABSENCE

 

5.01Executive
shall be entitled to 17 business days of paid time off (“PTO”) for each 12 months of employment, in addition
to the Company’s normal holidays. PTO includes sick days in excess of three sick days per calendar year provided by the
Company’s current sick leave policy, as well as leaves of absences and vacations. PTO will be scheduled after taking into
account the Executive’s duties and obligations at the Company. PTO and sick leave and all other leaves of absence will be
taken in accordance with the Company’s stated personnel policies and upon agreement with the Chief Executive Officer or
the Board. Upon termination or expiration of the Executive’s employment, Executive shall be entitled to compensation for
any accrued, unused PTO time in accordance with the Company’s PTO policy as of date of termination.

 

Article
6

TERMINATION

 

6.01The
Company may terminate Executive’s employment at any time, with or without Cause (as defined in Section 6.07), upon written
notice to Executive. For the purposes of this Agreement, an election by the Company not to extend employment pursuant to Section 3.01
shall be deemed a termination without Cause.

 

6.02Executive’s
employment will terminate as of the date of the death or Disability of the Executive. “Disability” shall mean
a determination by the Board that Executive is unable to perform the essential functions of his job under this Agreement due to
illness, injury, or other condition of a physical or psychological nature, with or without a reasonable accommodation for a period
aggregating to 90 days in any 12-month period. Such determination shall be made in good faith by the Board, the decision of which
shall be conclusive and binding. For clarity, the essential function of Executive’s job specifically include, but are not
limited to, Executive’s consistent performance of his obligations under Sections 1.02, 2.01, and 2.02 of this Agreement.

 

6.03On
any termination of employment, Executive will be entitled to receive:

 

		(a)	Base
                                         Salary for services performed through the date of such termination, payable on a pro-rated
                                         basis at the end of the month in which termination occurs;

 

    	3

    	 

    

 

		(b)	accrued
                                         and unpaid PTO in accordance with Article 5;

 

		(c)	any
                                         interest that Executive may have as a terminated employee in the Company’s 401(k)
                                         plan or other plans in which he participated, but only as required or permitted under
                                         the terms of such plans; and

 

		(d)	other
                                         than upon a termination by the Company for Cause or by the Executive other than for Good
                                         Reason, a pro-rated portion of any bonus otherwise due under Section 4.02 above, provided
                                         that such payment is consistent with the terms of such bonus plan (the “Prorated
                                         Bonus”) and that the requirement relating to the Release (as defined below)
                                         is satisfied. Any such bonus will be pro-rated based upon the number of full months Executive
                                         worked in the calendar year in which any such bonus was earned.

 

If
(x) Executive terminates Executive’s employment for Good Reason or (y) the Company terminates Executive’s employment
without Cause, Executive will be paid an amount equal to six months of his Base Salary, less customary withholdings (the “Severance
Payments”). The Severance Payments will be paid in installments at the Company’s regular payroll intervals commencing
on the first regular payroll date of the Company that occurs after the 60th day following Employee’s termination (the “Payment
Date”), with amounts in respect of the period preceding the Payment Date to be paid in a lump sum on the Payment Date.
In addition, if Executive is eligible to and elects to continue medical coverage from the Company as provided by law (commonly
referred to as COBRA), and continues to pay Executive’s portion of the monthly medical insurance premiums, the Company will
continue to pay the Company’s portion of the monthly medical insurance premiums paid at the time of termination for COBRA
coverage for Executive and his eligible dependents for a period of one year after termination of employment (the “Severance
Benefit”).

 

Upon
a termination for any other reason, including a voluntary resignation without Good Reason or a termination for Cause, Executive
will receive only the amounts set forth in (a), (b) (c) and (d) above (to the extent set forth above).

 

6.04During
the term of his employment and for 12 months after the date of Executive’s termination of employment, (i) Executive shall
not, directly or indirectly, make or publish any disparaging statements (whether written or oral) regarding the Company or any
of its then-affiliated companies or businesses, or the affiliates, directors, officers, agents, principal shareholders or customers
of any of them and (ii) the Company’s directors and officers shall not directly or indirectly, make or publish any disparaging
statements (whether written or oral) regarding Executive. Information which a Company director or officer or Executive is required
to make or disclose regarding the other to comply with laws or regulations, or makes in a pleading on the advice of litigation
counsel, and information which a Company director or officer needs to disclose for legitimate business reasons (for example disclosure
to the Company’s insurers or business associates), shall not constitute a disparaging statement.

 

6.05Upon
any termination of Executive’s employment with the Company, Executive will immediately return to the Company all equipment,
property and documents of the Company, including, specifically all property and documents containing any Confidential Information
(as defined in Section 8.01).

 

    	4

    	 

    

 

6.06Upon
any termination of Executive’s employment with the Company, Executive shall be deemed to have resigned from all other positions
he then holds as an officer, employee or director or other independent contractor of the Company or any of its subsidiaries or
affiliates, unless otherwise agreed by the Company and Executive in writing, and Executive will execute all documents reasonably
requested of him to confirm such resignations.

 

6.07Any
of the following events shall constitute “Cause”:

 

		(a)	any
                                         conviction or nolo contendere plea by Executive to a felony, gross misdemeanor, a misdemeanor
                                         involving moral turpitude, or any conduct by Executive that has or can reasonably be
                                         expected to have a detrimental effect on the Company or its image, or the image or reputation
                                         of its management, the Company’s customers, or its employees;

		(b)	any
                                         act of misconduct involving dishonesty which is injurious to the Company, any willful
                                         or gross negligence in the performance of duties, or any breach of fiduciary or other
                                         duty with respect to the Company;

		(c)	any
                                         material breach of this Agreement or of the Company’s published or written rules,
                                         codes or polices; provided, however, that such breach shall not constitute Cause if Executive
                                         cures or remedies such breach within 15 days after written notice to Executive, without
                                         material harm or loss to the Company, unless (i) such breach is part of a pattern of
                                         chronic breaches of the same, which may (but shall not be required to) be evidenced by
                                         a report or warning letter given by the Company to Executive; or (ii) such breach is
                                         of a nature that it is reasonably deemed by the Board not to be curable, including situations
                                         where the Board reasonably determines that harm or loss to the Company has already occurred
                                         or can reasonably be expected to occur and cannot be eliminated by such cure;

		(d)	any
                                         act of insubordination by Executive; provided, however, an act of insubordination by
                                         Executive shall not constitute Cause if Executive cures or remedies such insubordination
                                         within 15 days after written notice to Executive, without material harm or loss to the
                                         Company, unless (i) such insubordination is a part of a pattern of chronic insubordination,
                                         which may be evidenced by a report or warning letter given by the Company to Executive;
                                         or (ii) such insubordination is of a nature that it is reasonably deemed by the Board
                                         not to be curable, including situations where the Board reasonably determines that harm
                                         or loss to the Company has already occurred or can reasonably be expected to occur and
                                         cannot be eliminated by such cure;

		(e)	any
                                         disclosure of any Company trade secret or Confidential Information other than for the
                                         legitimate business purposes of the Company or as required by law, or conduct constituting
                                         unfair competition with respect to the Company, including intentionally inducing a party
                                         to breach a contract with the Company; or

    	5

    	 

    

 

		(f)	a
                                         willful violation of federal or state securities laws or employment laws.

 In
making such determination of Cause, the Board shall act in good faith and give Executive a reasonably detailed written notice
in advance of the termination. A resolution providing for the termination of Executive’s employment for Cause must be approved
by a majority of the members of the Board; provided, however, that if Executive is a member of the Board, he shall not vote on
the resolution shall not be deemed to be a member of the Board for purposes of whether a majority of its members have approved
such termination. Executive’s employment shall be deemed terminated for Cause upon the approval by the Board of a resolution
terminating Executive’s employment for Cause unless a later time or date is specified. For purposes of this Agreement, no
act or failure by the Executive shall be considered “willful” if such act is done by Executive in good faith in the
belief that such act is or was lawful and in the best interest of the Company or one or more of its businesses. In the event of
a termination for Cause, and not withstanding any contrary provision otherwise stated, Executive shall receive only those amounts
set forth in Section 6.03(a), 6.03(b), 6.03(c) and 6.03(d).

 

6.08Executive
may terminate his employment upon 60 days prior written notice to the Company for Good Reason. For purposes of this Agreement,
“Good Reason” means any of the following events or actions taken by the Company without Cause, and without
circumstances existing that would constitute Cause:

 

		(a)	the
                                         Company or any of its subsidiaries reduces Executive’s Base Salary, or otherwise
                                         changes benefits provided to Executive under compensation and benefit plans to be materially
                                         less favorable to Executive, other than reductions in Base Salary permitted under Section
                                         4.01 and other than changes to compensation and benefit plans generally applicable to
                                         senior executives of the Company;

		(b)	without
                                         Executive’s express written consent, the Company or any of its subsidiaries significantly
                                         reduces Executive’s job authority and responsibility, except as permitted under
                                         Section 1.02;

		(c)	without
                                         Executive’s express written consent, the Company or any of its subsidiaries requires
                                         Executive to change the location of Executive’s job or office, to a location more
                                         than 50 miles from the location of Executive’s job or office immediately prior
                                         to such required change that materially increases Executive’s commute;

		(d)	a
                                         successor company fails or refuses to assume the Company’s obligations under this
                                         Agreement; or

		(e)	the
                                         Company or any successor company breaches any of the material provisions of this Agreement.

    	6

    	 

    

 

If
Executive intends to terminate this Agreement for Good Reason, Executive must give not less than 60 days prior written notice
to the Company of the facts or events giving rise to Good Reason, and must give such notice within 90 days following the facts
or event alleged to give rise to Good Reason. The Company shall, within such 60-day notice period, have the right to cure or remedy
events or any action or event constituting “Good Reason” within the meaning of this Section 6.08. Executive’s
employment shall terminate on the 61st day after the notice is given if the Company fails to cure or remedy events
or any action or event constituting “Good Reason”. The failure to give such notice shall be deemed a waiver of the
right to terminate this Agreement for Good Reason based on such fact or event.

 

6.09Notwithstanding
the foregoing, any Severance Payments, Severance Benefits and Prorated Bonus payable to Executive in connection with termination
of Executive’s employment will be subject to the provisions of Section 7 and conditioned on Executive signing and not rescinding
a conventional separation agreement and mutual release in form and substance acceptable to the Company (the “Release”),
which agreement shall include, at a minimum, a full and general release of all claims (including employment-related claims) to
the greatest extent allowed by applicable law, a covenant not to sue, and an agreement to be reasonably available for consultation
and assistance to the Company during any period in which severance is paid, and an agreement to return to the Company all Company
property and copies thereof in any form or media. The Release will be delivered to the Executive within 5 days following the termination
of Executive’s employment and must be executed and become irrevocable by its terms no later than the 60th day following
the termination of Executive’s employment.

 

6.10The
provisions of Sections 6.04, 6.05, 6.06 and 6.09 shall survive the termination of this Agreement.

 

Article
7

SECTION
409A

 

7.01Compliance.
Notwithstanding anything herein to the contrary, this Agreement is intended to be interpreted and applied so that the payments
and benefits set forth herein either shall either be exempt from the requirements of Section 409A of the Internal Revenue Code
of 1986, as amended (the “Code”), or shall comply with the requirements of Code Section 409A, and, accordingly,
to the maximum extent permitted, this Agreement shall be interpreted to be exempt from or in compliance with Code Section 409A.
To the extent that the Company determines that any provision of this Agreement would cause the Executive to incur any additional
tax or interest under Code Section 409A, the Company shall be entitled to reform such provision to attempt to comply with or be
exempt from Code Section 409A through good faith modifications. To the extent that any provision hereof is modified in order to
comply with Code Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible,
maintain the original intent and economic benefit to Executive and the Company without violating the provisions of Code Section
409A. Notwithstanding anything herein to the contrary, in no event does the Company, its affiliates, officers, equityholders,
employees, agents, members, directors, or representatives guarantee the exemption from or compliance with Code Section 409A and
no such party shall have any liability for failure of this Agreement to be exempt from or comply with such Code section.

 

    	7

    	 

    

 

7.02Separate
Payments. Notwithstanding anything in this Agreement to the contrary, each payment payable hereunder shall be deemed to be a payment
in a series of separate payments for purposes of Code Section 409A.

 

7.03Specified
Employee. Notwithstanding any provision in this Agreement or elsewhere to the contrary, if on the date of Executive’s termination
from employment with the Company, Executive is deemed to be a “specified employee” within the meaning of Code Section
409A and the Final Treasury Regulations using the identification methodology selected by the Company from time to time, or if
none, the default methodology under Code Section 409A, any payments or benefits that constitute non-exempt deferred compensation
under Code Section 409A and that are due upon a termination of Executive’s employment shall be delayed and paid or provided
(or commence, in the case of installments) on the first payroll date on or following the earlier of (i) the date which is six
(6) months and one (1) day after Executive’s termination of employment for any reason other than death, and (ii) the date
of Executive’s death, and any remaining payments and benefits shall be paid or provided in accordance with the normal payment
dates specified for such payment or benefit.

 

7.04(iv)Separation
from Service. Notwithstanding anything in this Agreement or elsewhere to the contrary, a termination of employment shall not be
deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits that
constitute “non-qualified deferred compensation” within the meaning of Code Section 409A upon or following a termination
of Executive’s employment unless such termination is also a “separation from service” within the meaning of
Code Section 409A and, for purposes of any such provision of this Agreement, references to a “termination,” “termination
of employment” or like terms shall mean “separation from service” and the date of such separation from service
shall be the date of termination of Executive’s employment by the Company for purposes of any such payment or benefits.

 

7.05No
Designation. In no event may Executive, directly or indirectly, designate the calendar year of any payment to be made under this
Agreement or otherwise which constitutes a “deferral of compensation” within the meaning of Code Section 409A.

 

7.06Expense
Reimbursement. With regard to any provision herein that provides for reimbursement of costs and expenses or in-kind benefits,
except as permitted by Code Section 409A, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation
or exchange for another benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits, provided during
any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable
year, and (iii) such payments shall be made on or before the last day of Executive’s taxable year following the taxable
year in which the expense was incurred

 

    	8

    	 

    

 

Article
8

NONDISCLOSURE
AND INVENTIONS

 

8.01Except
as permitted or directed by the Company or as may be required in the proper discharge of Executive’s employment hereunder,
Executive shall not, during his employment or at any time thereafter, divulge, furnish or make accessible to anyone or use in
any way any Confidential Information. “Confidential Information” means any information or compilation of information
regarding the Company or its subsidiaries or affiliates that the Executive learns or develops during the course of his/her employment
that is not generally known by persons outside the Company (whether or not conceived, originated, discovered, or developed in
whole or in part by Executive). “Confidential Information” includes but is not limited to the following types of information
and other information of a similar nature (whether or not reduced to writing), all of which Executive agrees constitutes the valuable
trade secrets: research, designs, development, know how, computer programs and processes, marketing plans and techniques, existing
and contemplated products and services, potential and actual customer and product names and related information, prices, sales,
inventory, personnel, computer programs and related documentation, technical and strategic plans, and finances. “Confidential
Information” also includes any information of the foregoing nature that the Company treats as proprietary or designates
as Confidential Information, whether or not owned or developed by the Company. “Confidential Information” does not
include information that (a) is or becomes generally available to the public through no fault of Executive, (b) was known to Executive
prior to its disclosure by the Company, as demonstrated by files in existence at the time of the disclosure, (c) becomes known
to Executive, without restriction, from a source other than the Company, without breach of this Agreement by Executive and otherwise
not in violation of the Company’s rights, or (d) is explicitly approved for release by written authorization of the Company.

 

8.02Executive
acknowledges and agrees that all inventions, innovations, improvements, developments, methods, designs, trade secrets, analyses,
drawings, reports and all similar related information (whether or not patentable) which relate to the Company’s or any of
its subsidiaries’ actual or anticipated business, research and development or existing products or services and which are
conceived, developed or made by Executive while employed by the Company or any of its subsidiaries (“Work Product”)
belong to the Company or such subsidiary. Executive shall promptly disclose such Work Product to the Board and, at the Company’s
expense, perform all actions reasonably requested by the Board (whether during or after employment by the Company) to establish
and confirm such ownership (including, without limitation, assignments, consents, powers of attorney and other instruments). For
purposes of this Agreement, any Work Product or other discoveries relating to the business of the Company or any subsidiaries
on which Executive files or claims a copyright or files a patent application, during the Term of this Agreement, shall be presumed
to be Work Product conceived or developed by Executive in whole or in part during the term of his employment with the Company,
subject to proof to the contrary by good faith, written and duly corroborated records establishing that such Work Product was
conceived and made following termination of employment.

 

Notwithstanding
the foregoing, the Company advises Executive, and Executive understands and agrees, that the foregoing does not apply to inventions
or other discoveries for which no equipment, supplies, facility or trade secret information of the Company was used and that was
developed entirely on Executive’s own time, and (a) that does not relate (i) directly to the Company’s business or
(ii) to the Company’s actual or demonstrably anticipated business research or development, or (b) that does not result from
any work performed by Executive for the Company.

 

    	9

    	 

    

 

8.03In
the event of a breach or threatened breach by Executive of the provisions of this Article 8, the Company shall be entitled to
an injunction restraining Executive from directly or indirectly disclosing, disseminating, lecturing upon, publishing or using
such confidential, trade secret or proprietary information (whether in whole or in part) and restraining Executive from rendering
any services or participating with any person, firm, corporation, association or other entity to whom such knowledge or information
(whether in whole or in part) has been disclosed, without the posting of a bond or other security. Nothing herein shall be construed
as prohibiting the Company from pursuing any other equitable or legal remedies available to it for such breach or threatened breach,
including the recovery of damages from Executive.

 

8.04Executive
agrees that all notes, data, reference materials, documents, business plans, business and financial records, computer programs,
and other materials that in any way incorporate, embody, or reflect any of the Confidential Information, whether prepared by Executive
or others, are the exclusive property of the Company, and Executive agrees to forthwith deliver to the Company all such materials,
including all copies or memorializations thereof, in Executive’s possession or control, whenever requested to do so by the
Company, and in any event, upon termination of Executive’s employment with the Company.

 

8.05The
Executive understands and agrees that any violation of this Article 8 while employed by the Company may result in immediate disciplinary
action by the Company, including termination of employment for Cause.

 

8.06The
provisions of this Article 8 shall survive termination of this Agreement indefinitely.

 

Article
9

NON-COMPETITION,
NON-INTERFERENCE AND NON-SOLICITATION

 

9.01In
further consideration of the compensation and benefits that have been provided to Executive and will be provided to Executive
hereunder, Executive acknowledges that in the course of his employment with the Company he will become familiar with Confidential
Information and that his services have been and will be of a special, unique and extraordinary value to the Company, and therefore,
Executive agrees that, during the period of his employment, and for a period of one year following the termination of Executive’s
employment with the Company, he shall not directly or indirectly own any interest in, manage, control, participate in, consult
with, render services for, or in any manner engage in any business competing with the business of the Company, its subsidiaries
or affiliates, as defined below, and as such businesses exist or are developing during the period of his employment, within any
geographical area in which the Company or its subsidiaries or affiliates engage or have defined plans to engage in such businesses.
Nothing herein shall prevent Executive from being a passive owner of not more than 2% of the outstanding stock of any class of
a corporation which is publicly traded, so long as Executive has no participation in the business of such corporation. For the
purposes of this Agreement, “business” or “business of the Company” means, with respect to and including
the Company and its subsidiaries or affiliates, the design, development, marketing and sale of digital signage products and solutions.

 

    	10

    	 

    

 

9.02Executive
agrees that during the term of his employment and for a period of one year after the termination of Executive’s employment
he will not directly or indirectly (i) in any way interfere or attempt to interfere with the Company’s relationships with
any of its current or potential customers, vendors, investors, business partners, or (ii) employ or attempt to employ any of the
Company’s employees, including those who were employees at the Company during the 12 months prior to Employee’s termination
at the Company, on behalf of any other entity, whether or not such entity competes with the Company.

 

9.03Executive
agrees that breach by him of the provisions of this Article 9 will cause the Company irreparable harm that is not fully remedied
by monetary damages. In the event of a breach or threatened breach by Executive of the provisions of this Article 9, the Company
shall be entitled to an injunction restraining Executive from directly or indirectly competing or recruiting as prohibited herein,
without posting a bond or other security, and, if the Company is successful in establishing a breach, to its reasonable attorneys’
fees and costs. Nothing herein shall be construed as prohibiting the Company from pursuing any other equitable or legal remedies
available to it for such breach or threatened breach, including the recovery of damages from Executive.

 

9.04Executive
understands and agrees that any violation of this Article 9 while employed by the Company may result in immediate disciplinary
action by the Company, including termination of employment for Cause.

 

9.05Executive
acknowledges that the covenants in this Article 9 have been conditions of, and were incidents to, his initial employment, and
that these covenants are supported by additional and adequate consideration and are fully enforceable in accordance with their
terms.

 

9.06The
obligations contained in this Article 9 shall survive the termination of this Agreement as described in this Article 9.

 

Article
10

MISCELLANEOUS

 

10.01Governing
Law. This Agreement shall be governed and construed according to the laws of the State of New York without regard to conflicts-of-law
provisions. The Company and Executive agree that if any action is brought pursuant to this Agreement that is not otherwise required
to be resolved by arbitration pursuant to Section 10.06, such dispute shall be resolved only in the state courts in New York,
New York, or the United States District Court for the Southern District of New York, and each party hereto unconditionally (a)
submits for itself in any proceeding relating to this Agreement, or for recognition and enforcement of any judgment in respect
thereof, to the exclusive jurisdiction of the state courts in New York, New York, or the United States District Court for the
Southern District of New York, and agrees that all claims in respect to any such proceeding shall be heard and determined in state
courts in New York, New York, or, to the extent permitted by law, the United States District Court for the Southern District of
New York, (b) consents that any such proceeding may and shall be brought in such courts and waives any objection that it may now
or thereafter have to the venue or jurisdiction of any such proceeding in any such court or that such proceeding was brought in
an inconvenient court and agrees not to plead or claim the same; (c) waives all right to trial by jury in any proceeding (whether
based on contract, tort or otherwise) arising out of or relating to this Agreement, or its performance under or the enforcement
of this Agreement; (d) agrees that service of process in any such proceeding may be effected by mailing a copy of such process
by registered or certified mail (or any substantially similar form of mail), postage prepaid, to such party at its address as
provided in Section 10.08; and (e) agrees that nothing in this Agreement shall affect the right to effect service of process in
any other manner permitted by the laws of the State of New York.

 

    	11

    	 

    

 

10.02Successors.
This Agreement is personal to Executive and Executive may not assign or transfer any part of his rights or duties hereunder, or
any compensation due to him hereunder, to any other person or entity. This Agreement may be assigned by the Company. The Company
shall require any successor or assignee, whether direct or indirect, by purchase, merger, consolidation or otherwise, of all or
substantially all the business or assets of the Company, expressly and unconditionally to assume and agree to perform the Company’s
obligations under this Agreement, in the same manner and to the same extent that the Company would be required to perform if no
such succession or assignment had taken place. In such event, the term “Company,” as used in this Agreement, shall
mean the Company as defined above and any successor or assignee to its business or assets that by reason hereof becomes bound
by the terms and provisions of this Agreement.

 

10.03Waiver.
The waiver by the Company of the breach or nonperformance of any provision of this Agreement by Executive will not operate or
be construed as a waiver of any future breach or nonperformance under any such provision or any other provision of this Agreement
or any similar agreement with any other Executive.

 

10.04Entire
Agreement; Modification. This Agreement supersedes, revokes and replaces any and all prior oral or written understandings, if
any, between the parties relating to the subject matter of this Agreement. The parties agree that this Agreement: (a) is the entire
understanding and agreement between the parties; and (b) is the complete and exclusive statement of the terms and conditions thereof,
and there are no other written or oral agreements in regard to the subject matter of this Agreement. Except for modifications
described in Section 1.02, 3.01 and 4.01, this Agreement shall not be changed or modified except by a written document signed
by the parties hereto.

 

10.05Severability
and Blue Penciling. To the extent that any provision of this Agreement shall be determined to be invalid or unenforceable as written,
the validity and enforceability of the remainder of such provision and of this Agreement shall be unaffected. If any particular
provision of this Agreement shall be adjudicated to be invalid or unenforceable, the Company and Executive specifically authorize
the tribunal making such determination to edit the invalid or unenforceable provision to allow this Agreement, and the provisions
thereof, to be valid and enforceable to the fullest extent allowed by law or public policy.

 

    	12

    	 

    

 

10.06Arbitration.
Any dispute, claim or controversy arising under this Agreement shall, at the request of any party hereto be resolved by binding
arbitration in New York, New York by a single arbitrator selected by the Company and Executive, with arbitration governed by The
United States Arbitration Act (Title 9, U.S. Code); provided, however, that a dispute, claim or controversy shall be subject to
adjudication by a court in any proceeding against the Company or Executive involving third parties (in addition to the Company
or Executive). Such arbitrator shall be a disinterested person who is either an attorney, retired judge or labor relations arbitrator.
In the event the Company and Executive are unable to agree upon such arbitrator, the arbitrator shall, upon petition by either
the Company or Executive, be designated by a judge of the Hennepin County District Court. The arbitrator shall have the authority
to make awards of damages as would any court in New York having jurisdiction over a dispute between employer and Executive, except
that the arbitrator may not make an award of exemplary damages or consequential damages. In addition, the Company and Executive
agree that all other matters arising out of Executive’s employment relationship with the Company shall be arbitrable, unless
otherwise restricted by law.

 

		(a)	In
                                         any arbitration proceeding, each party shall pay the fees and expenses of its or his
                                         own legal counsel.

		(b)	The
                                         arbitrator, in his or her discretion, shall award legal fees and expenses and costs of
                                         the arbitration, including the arbitrator’s fee, to a party who substantially prevails
                                         in its claims in such proceeding.

		(c)	Notwithstanding
                                         this Section 10.06, in the event of alleged noncompliance or violation, as the case may
                                         be, of Article 8 or Article 9 of this Agreement, the
	 	 	 
	 	 	Company
may, at its discretion, alternatively apply to a court of competent jurisdiction for a temporary restraining order, injunctive
and/or such other legal and equitable remedies as may be appropriate.

10.07Legal
Fees. If any contest or dispute shall arise between the Company and Executive regarding any provision of this Agreement, and such
dispute results in court proceedings or arbitration, a party that prevails with respect to a claim brought and pursued in connection
with such dispute shall be entitled to recover its legal fees and expenses reasonably incurred in connection with such dispute.
Such reimbursement shall be made as soon as practicable following the resolution of the dispute (whether or not appealed) to the
extent a party receives documented evidence of such fees and expenses.

 

10.08Withholding.
The Company may withhold from any amounts payable under this Agreement all federal, state, city or other taxes, and other amounts
required by applicable law to be withheld by the Company.

10.09Notices.
For purposes of this Agreement, notices and all other communications provided for herein shall be in writing and shall be deemed
to have been duly given when personally delivered or sent by certified mail, return receipt requested, postage prepaid, addressed
to Executive at his residence address appearing on the records of the Company and to the Company at its then-current executive
offices to the attention of the Chief Executive Officer or Board. All notices and communications shall be deemed to have been
received on the date of delivery thereof or on the third business day after the mailing thereof, except that notice of change
of address shall be effective only upon actual receipt. No objection to the method of delivery may be made if the written notice
or other communication is actually received.

 

10.10Survival.
The provisions of this Article 10 shall survive the termination of this Agreement, indefinitely.

*
* * * * * * *

 

    	13

    	 

    

 

IN
WITNESS WHEREOF, the parties have executed this Employment Agreement to be effective as of the date first set forth above.

 

	 	WIRELESS RONIN TECHNOLOGIES, INC.  
	 	 
	 	/s/ John Walpuck
	 	Name: John Walpuck
	 	Title: Chief Financial officer
	 	 
	 	EXECUTIVE:
	 	 
	 	/s/ Paul Price
	 	Paul Price

 

 

Signature
Page – Executive Employment Agreement

(Paul
Price)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00234-of-00352.parquet"}]]